Filing Flows › Rhythm Pharmaceuticals (RYTM) › Q1 2026
Rhythm Pharmaceuticals (RYTM) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Rhythm Pharmaceuticals (RYTM) reported revenue of $60.1M for the first quarter 2026 (Q1 2026), +84% from a year earlier and +5% from the quarter before. Operating margin was -87.1%, net loss $55.6M (92.6% of revenue).
Rhythm Pharmaceuticals, Q1 2026: revenue $60.1M (+84% year over year), operating margin -87.1%, net loss $55.6M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $60.1M | +5% | +84% |
| Operating profit | −$52.4M | — | — |
| Net earnings | −$55.6M | — | — |
| Operating cash flow | −$44.2M | — | — |
What changed
Revenue was $60.1M in Q1 2026, up 84% year over year and up 5% from the previous quarter.
Operating costs exceeded revenue by $52.4M, an operating margin of -87.1%. Total costs grew 41% against revenue growth of 84%. The fastest-growing cost line was Cost of revenue (+96%). The quarter ended with a net loss of $55.6M, wider than the previous quarter's $47.5M loss.
Operating cash flow was −$44.2M. Non-cash charges added back $23.1M of share-based compensation. Working capital and other items used $11.6M.
Questions
What was Rhythm Pharmaceuticals' revenue in the first quarter 2026?
Rhythm Pharmaceuticals (RYTM) reported revenue of $60.1M for the first quarter 2026 (Q1 2026), +84% from a year earlier and +5% from the quarter before.
Was Rhythm Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $52.4M (-87.1% of revenue) and net loss $55.6M.